9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha) for penile neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Jun 2024: Trial registered, NCT06465914
  2. 11 Jul 2024: Trial started, NCT06465914

The trials

NCT06465914: A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

State
Under way
Phase
Phase 3
People
9,000 taking part
Started
11 Jul 2024
Primary completion
30 Jul 2027
Arms
9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine
Results
None posted
  1. 20 Jun 2024: Trial registered
  2. 11 Jul 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.